In a report issued on July 20, James McIlree from Dawson James maintained a Buy rating on Better Choice Company (BTTR – Research Report), with a price target of $10.00. The company’s shares closed last Friday at $2.19.
According to TipRanks.com, McIlree has 0 stars on 0-5 stars ranking scale with an average return of -13.9% and a 31.8% success rate. McIlree covers the Technology sector, focusing on stocks such as Smith Micro Software, Byrna Technologies, and Oblong.
Currently, the analyst consensus on Better Choice Company is a Moderate Buy with an average price target of $10.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $4.30 and a one-year low of $1.70. Currently, Better Choice Company has an average volume of 111.4K.
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BTTR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Better Choice Co., Inc. is an animal health and wellness cannabidiol(CBD) company. The firm acquired TruPet LLC, an online seller of ultra-premium all natural pet food, treats and supplements, with a special focus on freeze dried and dehydrated raw products and Bona Vida, Inc., an innovative emerging CBD platform, focused on developing a portfolio of brand and product verticals within the animal and human health and wellness space. Its brands include Trucut, Bona Vida, Orapup, Rawgo, and Trudog. The company was founded on January 3, 2001 and is headquartered in Oldsmar, FL.
Read More on BTTR:
- Dawson James Sticks to Their Buy Rating for Mesabi Shs (MSB)
- Analysts Offer Insights on Technology Companies: Calix (CALX) and Twitter (TWTR)
- Sagicor Financial (SGCFF) Receives a Buy from RBC Capital
- Morgan Stanley Thinks Plug Power’s Stock is Going to Recover
- Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC) and Hookipa Pharma (HOOK)
